Common stock, par value $0.0001 per share
- Symbol
- PEPG
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Quarterly Report · 10-Q
PEPGNASDAQEQUITYCurrent
PepGen Inc. is a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
PEPGEN INC. · 10-Q · Filed 2026-08-06